Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Safety issue puts daclizumab in doubt for MS
Sanofi withdraws Campath in US and EU
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
A high-density screen for linkage in multiple sclerosis.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Multiple sclerosis.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Biomarkers for Brain Disorders: Challenges and Opportunities
Mitochondrial approaches for neuroprotection.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.

Pages